RxDoctor Payments Data

Sylvia Soto Davila

Physician Assistant · Pembroke Pines, FLNPI 1811150543

Payments from drug & device makers

$4,515in general payments, 2019–2025

Across 107 payments — averaging $42.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Johnson & Johnson$573
  • GSK$518
  • Novo Nordisk$473
  • Boehringer Ingelheim$431
  • Lilly USA, LLC$370
  • plus $480 from 8 others

What the payments were for

  • Food & beverage$4,508100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,515 in reported general payments places this provider in the 85th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$13,484
Medicare patients
37
Services billed
227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol61$56,249
JardianceEmpagliflozin39$53,340
OzempicSemaglutide28$42,728
MounjaroTirzepatide32$39,581
XareltoRivaroxaban23$28,822
EliquisApixaban20$25,140
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$20,727
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$19,554
Repatha SyringeEvolocumab18$10,729
Xigduo XrDapaglifloz Propaned/Metformin12$8,818
Albuterol Sulfate HfaAlbuterol Sulfate79$2,850
Rosuvastatin Calcium159$2,603
Levothyroxine Sodium203$2,340
Atorvastatin Calcium296$2,192
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,671$76,97582 claims
Boehringer IngelheimJardiance$431$53,34039 claims
Novo NordiskOzempic$473$42,72828 claims
Lilly USA, LLCMounjaro$370$39,58132 claims
Johnson & JohnsonXarelto$573$28,82223 claims
PfizerEliquis$93$25,14020 claims
GSKTrelegy Ellipta$518$19,55417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →